OrthoCor Medical » Plantar Fasciitis Clinical Study Complete – Results to Follow Soon!

News & Blog

Plantar Fasciitis Clinical Study Complete – Results to Follow Soon!

We have exciting news! Our clinical trial examining the treatment of plantar fasciitis with Pulsed Electromagnetic Field (PEMF) therapy from our Active System is complete. Plantar fasciitis is a common, painful foot condition that roughly 10% of individuals are anticipated to experience at least once during their lifetime (Uden et al., 2011). The plantar fascia is a band of tissue that connects the heel bone and base of the toes. The simple act of walking can be painful for those with the condition, and often worse right after waking up in the morning. While numerous treatments exist for plantar fasciitis, they tend to be focused on reducing the pain – not ending the condition itself. Additionally, such treatments are often at odds with the demands of daily life, where regular movement continues to irritate the tissue and exacerbate the condition. When more conservative treatments fail, patients often turn to steroid injections. These injections can produce significant and painful side effects.

A variety of clinical studies have already demonstrated the significant impact PEMF has on pain reduction and natural healing. These studies are often focused on self-reported levels of pain and activity from participants, such as a 2012 study which measured morning pain from plantar fasciitis during PEMF therapy (Brook et al., 2012). In addition to recording similar scores for patient pain and function, our study measured the physical dimensions of abnormal fascial tissue. These damaged areas and scar tissue are denser and less flexible than healthy tissue, and often found in plantar fascia cases. Such tissue is termed “hypoechoic” because it responds differently to ultrasound examination. Our study repeatedly measured the size of these hyperechoic regions to see how they respond to PEMF treatment.

While we’re not releasing our full results yet, we’ll let Kai Kroll, our head of Research & Development, provide some insight.

“Preliminary analysis of the data shows excellent results. The ultrasound-measured hypoechoic area has demonstrated statistically significant reduction over the 12-week study. We are pleased to see that the quantified ultrasound measurements validate improvements in patient pain and function scores.”

-Kai Kroll, Head of R&D for Caerus Corp and OrthoCor Medical-

We look forward to providing our full results soon, and are equally excited to unveil additional clinical designs in the near future.


Comments are closed.


Get relief today. Call us 888.583.6268

Leave your email to stay in touch with our latest news!

Thank you for your upload